These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1083 related items for PubMed ID: 26122176

  • 1. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, Piché A.
    BMC Cancer; 2015 Jul 01; 15():492. PubMed ID: 26122176
    [Abstract] [Full Text] [Related]

  • 2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D'Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A.
    J Exp Clin Cancer Res; 2017 May 08; 36(1):63. PubMed ID: 28482906
    [Abstract] [Full Text] [Related]

  • 3. Intratumoral interleukin-6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring.
    Masoumi-Moghaddam S, Amini A, Wei AQ, Robertson G, Morris DL.
    J Ovarian Res; 2015 Aug 19; 8():58. PubMed ID: 26282935
    [Abstract] [Full Text] [Related]

  • 4. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
    Kolomeyevskaya N, Eng KH, Khan AN, Grzankowski KS, Singel KL, Moysich K, Segal BH.
    Gynecol Oncol; 2015 Aug 19; 138(2):352-7. PubMed ID: 26001328
    [Abstract] [Full Text] [Related]

  • 5. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
    Wu WJ, Wang Q, Zhang W, Li L.
    Zhonghua Fu Chan Ke Za Zhi; 2016 Jul 25; 51(7):515-23. PubMed ID: 27465871
    [Abstract] [Full Text] [Related]

  • 6. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA, Sabaa BE, Abdelkhalik D, Mansour H, Melis M, Shaalan W, Farouk M, Malik E, Soliman AA.
    J Cancer Res Clin Oncol; 2016 May 25; 142(5):949-58. PubMed ID: 26762850
    [Abstract] [Full Text] [Related]

  • 7. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C, Lokman NA, Pyragius CE, Ween MP, Macpherson AM, Ruszkiewicz A, Hoffmann P, Oehler MK.
    Oncotarget; 2017 Mar 14; 8(11):17819-17832. PubMed ID: 28147318
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
    Zhang W, Niu C, He W, Hou T, Sun X, Xu L, Zhang Y.
    Tumour Biol; 2016 May 14; 37(5):6239-54. PubMed ID: 26615423
    [Abstract] [Full Text] [Related]

  • 12. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
    Vallius T, Hynninen J, Auranen A, Carpén O, Matomäki J, Oksa S, Virtanen J, Grénman S.
    Tumour Biol; 2014 Dec 14; 35(12):12389-95. PubMed ID: 25190018
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
    Shi J, Huo R, Li N, Li H, Zhai T, Li H, Shen B, Ye J, Fu R, Di W.
    BMC Cancer; 2019 Nov 25; 19(1):1140. PubMed ID: 31766991
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
    Zheng H, Gao Y.
    Int J Gynecol Cancer; 2012 Jul 25; 22(6):1000-5. PubMed ID: 22426406
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A.
    J Pathol; 2012 Apr 25; 226(5):746-55. PubMed ID: 22069160
    [Abstract] [Full Text] [Related]

  • 19. Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer.
    Arab M, Jamdar F, Sadat Hosseini M, Ghodssi- Ghasemabadi R, Farzaneh F, Ashrafganjoei T.
    Asian Pac J Cancer Prev; 2018 May 26; 19(5):1319-1324. PubMed ID: 29802693
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.
    Previs R, Leath CA, Coleman RL, Herzog TJ, Krivak TC, Brower SL, Tian C, Secord AA.
    Gynecol Oncol; 2015 Aug 26; 138(2):267-71. PubMed ID: 26037898
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.